Compare DEI & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | SLS |
|---|---|---|
| Founded | 1971 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2006 | 2007 |
| Metric | DEI | SLS |
|---|---|---|
| Price | $10.18 | $11.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 2 |
| Target Price | $12.40 | ★ $32.50 |
| AVG Volume (30 Days) | 2.0M | ★ 5.0M |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | ★ 7.47% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,982,000.00 | N/A |
| Revenue This Year | $1.79 | N/A |
| Revenue Next Year | $2.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $9.04 | $1.39 |
| 52 Week High | $13.32 | $15.88 |
| Indicator | DEI | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 47.50 |
| Support Level | $9.30 | $10.78 |
| Resistance Level | $10.59 | $12.62 |
| Average True Range (ATR) | 0.32 | 0.85 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 88.52 | 54.18 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.